Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2015 1
2018 1
2020 1
2021 1
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Adams D, Tournev IL, Taylor MS, Coelho T, Planté-Bordeneuve V, Berk JL, González-Duarte A, Gillmore JD, Low SC, Sekijima Y, Obici L, Chen C, Badri P, Arum SM, Vest J, Polydefkis M; HELIOS-A Collaborators. Adams D, et al. Amyloid. 2023 Mar;30(1):1-9. doi: 10.1080/13506129.2022.2091985. Epub 2022 Jul 23. Amyloid. 2023. PMID: 35875890 Clinical Trial.
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group. Adams D, et al. Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16. Lancet Neurol. 2021. PMID: 33212063 Clinical Trial.
Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation.
Schmidt HH, Wixner J, Planté-Bordeneuve V, Muñoz-Beamud F, Lladó L, Gillmore JD, Mazzeo A, Li X, Arum S, Jay PY, Adams D; Patisiran Post-LT Study Group. Schmidt HH, et al. Am J Transplant. 2022 Jun;22(6):1646-1657. doi: 10.1111/ajt.17009. Epub 2022 Mar 26. Am J Transplant. 2022. PMID: 35213769 Free PMC article. Clinical Trial.
A narrative review and expert recommendations on the assessment of the clinical manifestations, follow-up, and management of post-OLT patients with ATTRv amyloidosis.
Casasnovas C, Lladó L, Borrachero C, Pérez-Santamaría PV, Muñoz-Beamud F, Losada-López IA, Baliellas-Comellas MC, González-Moreno J. Casasnovas C, et al. Among authors: borrachero c. Ther Adv Neurol Disord. 2023 Aug 24;16:17562864231191590. doi: 10.1177/17562864231191590. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 37655225 Free PMC article. Review.
Illegible handwriting in medical records.
Rodríguez-Vera FJ, Marín Y, Sánchez A, Borrachero C, Pujol E. Rodríguez-Vera FJ, et al. Among authors: borrachero c. J R Soc Med. 2002 Nov;95(11):545-6. doi: 10.1177/014107680209501105. J R Soc Med. 2002. PMID: 12411618 Free PMC article.
Factors associated with poor anticoagulation control with vitaminK antagonists among outpatients attended in Internal Medicine and Neurology. The ALADIN study.
Contreras Muruaga MM, Reig G, Vivancos J, González A, Cardona P, Ramírez-Moreno JM, Martí-Fábregas J, Suárez Fernández C; en nombre de los investigadores del estudio ALADIN; Listado de investigadores del estudio ALADIN. Contreras Muruaga MM, et al. Rev Clin Esp (Barc). 2018 Oct;218(7):327-335. doi: 10.1016/j.rce.2018.04.020. Epub 2018 Jul 6. Rev Clin Esp (Barc). 2018. PMID: 29983190 English, Spanish.
[Recommendations regarding diagnosis and treatment of transthyretin familial amyloid polyneuropathy.Grupo de Estudio y Tratamiento de la Polineuropatía Amiloidótica Familiar por Transtiretina (GETPAF-TTR)].
García-Pavía P, Muñoz-Beamud F, Casasnovas C; en representación del Grupo de Estudio y Tratamiento de la Polineuropatía Amiloidótica Familiar por Transtiretina (GETPAF-TTR). García-Pavía P, et al. Med Clin (Barc). 2015 Sep 7;145(5):211-7. doi: 10.1016/j.medcli.2015.02.003. Epub 2015 Mar 24. Med Clin (Barc). 2015. PMID: 25817447 Spanish. No abstract available.